Hong Kong Stock Announces Nuggets | Yum China Announces Third Quarter Results, Net Profit of US$311 Million Increased 10% YoY

Zhitongcaijing · 1d ago

Important matters:

Kangzhe Pharmaceutical (00867): Singapore marketing license application for innovative drug rucotinib phosphate cream approved

Insili Intelligence (03696) plans to invest 302.5 million yuan to participate in the establishment of an investment fund

Benmao Technology (06731) signs a strategic cooperation agreement with a leading Korean intelligent robot company

Qingang Co., Ltd. (03369) plans to acquire Caofeidian high-quality bulk terminal assets and raise supporting capital from Hebei Port Group

Shoucheng Holdings (00697) subsidiary participated in investing in CICC Cainiao REIT

Dongpeng Beverage (09980) won industrial land in Zhengzhou for 98.05 million yuan to promote the construction of a production base in central China

Shiyao Group (01093): Phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and refractory hypertension was officially launched at the first research center in China

Chenlin Education (01593) enters into an acquisition framework agreement relating to possible acquisitions

Changjiang Life Technology (00775): Shunpu Pharmaceutical Technology will publish the latest pre-clinical data on the two cancer vaccines at SITC 2026

Cornerstone Pharmaceutical-B (02616) and Kimia Therapeutics reached a clinical development cooperation to jointly promote an innovative drug candidate targeting key repair pathways for solid tumors

Operating performance:

Yum China (09987) announced third quarter results, net profit of US$311 million increased 10% year over year